market-trends is the sole category represented across all 1 tracked stories. DefenCath is most often covered alongside Acorn Energy, Inc., which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about DefenCath
market-trends is the sole category represented across all 1 tracked stories. DefenCath is most often covered alongside Acorn Energy, Inc., which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 5.8 for that window. DefenCath appears in 1 tracked Healthcare story from March 6, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering DefenCath. Shared-story counts are live from our verified record — not editorial picks.
CorMedix and Acorn Energy reported strong Q4 2025 results, highlighting a year of significant commercial expansion for specialized healthcare and infrastructure solutions. CorMedix saw accelerated adoption of its antimicrobial catheter lock solution, DefenCath, while Acorn Energy’s OmniMetrix division capitalized on rising demand for remote monitoring in critical healthcare facilities.
